20074-67-3Relevant academic research and scientific papers
Examination of Pyridazine as a Possible Scaffold for Nucleophilic Catalysis
Tamaki, Airi,Kojima, Satoshi,Yamamoto, Yohsuke
, p. 8710 - 8721 (2016)
Pyridazines with amino groups positioned para to each aromatic ring nitrogen and fixed in six-membered rings were prepared. The representative symmetric amino N-Et derivative was found to slightly exceed DMAP in catalytic activity in the acetylation reaction of a tertiary alcohol in C6D6. Nucleophilicity eclipsing that of DMAP was established in competitive reactions using phenacyl bromide as the electrophile, and the unsymmetric N-Et derivative was revealed to have even higher nucleophilicity.
Chlorination of 3,4,5-trichloropyridazin-6-one and synthesis of 3,4,5-trichloro-1-(4,5,6-trichloropyridazin-3-yl)pyridazin-6-one
Kang,Woo Song Lee,Kim,Yoon,Shiro
, p. 1049 - 1053 (2000)
This paper presents the chlorination of 3,4,5-trichloropyridazin-6-one and the synthesis of 3,4,5-trichloro-1-(4,5,6-trichloropyridazin-3-yl)pyridazin-6-one.
Reaction of 4,5-dichloro-3-nitropyridazin-6-one with dimethylchloromethyleneammonium chloride
Kweon, Deok-Heon,Cho, Su-Dong,Kim, Sung-Kyu,Chung, Joo-Wha,Yoon, Yong-Jin
, p. 1915 - 1918 (1996)
3,4,5-Trichloropyridazin-6-one, 3,4,5,6-tetrachloropyridazine and 4,5-dichloro-3-(N,N-dimethylamino)pyridazin-6-one were synthesized from 4,5-dichloro-3-nitropyridazin-6-one and dimethylchloromethyleneammonium chloride selectively.
TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS
-
Page/Page column 71, (2013/03/26)
There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).
